Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading VBI Vaccines Inc. chart...

About the Company

vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.

Exchange

NASDAQ

$8M

Total Revenue

98

Employees

$13M

Market Capitalization

-0.07

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $VBIV News

Vbi Vaccines (NASDAQ: VBIV)

4d ago, source: The Motley Fool

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of ...

VBI Vaccines Secures Forbearance Agreement Extensions

1mon ago, source: Hosted on MSN

VBI Vaccines Inc. and its subsidiary faced challenges meeting the minimum net revenue requirements as stipulated in their Loan Agreement with K2 HealthVentures LLC. To address this, they entered ...

VBI Vaccines (VBIV) Provides Updates on COVID-19 Vaccine

1y ago, source: AOL

VBI Vaccines Inc. VBIV announced an update on the progress of its two vaccine candidates for COVID-19. The first one, VBI-2901, is a trivalent pan-coronavirus vaccine candidate expressing the SARS ...

VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split

11mon ago, source: Hosted on MSN

VBI Vaccines Inc. said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct a ...

VBI Vaccines, Inc. (VBIV) stock forecast and price target

2y ago, source: Yahoo Finance

Find the latest VBI Vaccines, Inc. VBIV analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

VBI Vaccines Inc VBIV

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

VBI Vaccines Inc VBIV

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

VBI Vaccines Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

VBI Vaccines Inc.

1mon ago, source: TheStreet.com

VBI VACCINES INC's gross profit margin for the third quarter of its fiscal year 2023 has significantly increased when compared to the same period a year ago. The company has grown sales and net ...

VBI Vaccines Inc. (VBIV)

11mon ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...